Veraxa Biotech AG
VRXAWHealthcare|Biotechnology|DE
$0.03
-0.00 (-13.79%)
About
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
Stock Price
-86.8%(1Y)
1M
-31.1%
3M
-73.8%
6M
-86.8%
YTD
-86.8%
1Y
-86.8%
3Y
-86.8%
5Y
-86.8%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$632.5K
Employees0
CEOChristoph Antz
IPO DateJun 10, 2026
Beta0.60
52-Week Range$0.025 – $0.35
Avg Volume58,806
ExchangeNASDAQ
Websiteveraxa.com
Ownership
Float49.8%
Shares Outstanding25.3M
Data last updated: Nov 9, 2026, 04:40 AM